JPWO2020023923A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020023923A5 JPWO2020023923A5 JP2021503108A JP2021503108A JPWO2020023923A5 JP WO2020023923 A5 JPWO2020023923 A5 JP WO2020023923A5 JP 2021503108 A JP2021503108 A JP 2021503108A JP 2021503108 A JP2021503108 A JP 2021503108A JP WO2020023923 A5 JPWO2020023923 A5 JP WO2020023923A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- compound
- acceptable salt
- fenfluramine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DBGIVFWFUFKIQN-SECBINFHSA-N Levofenfluramine Chemical compound CCN[C@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-SECBINFHSA-N 0.000 claims description 9
- MLBHFBKZUPLWBD-SSDOTTSWSA-N (2R)-1-[3-(trifluoromethyl)phenyl]-2-propanamine Chemical compound C[C@@H](N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-SSDOTTSWSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 5
- CJAVTWRYCDNHSM-CQSZACIVSA-N 2-[[(2r)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amino]ethyl benzoate Chemical compound C([C@@H](C)NCCOC(=O)C=1C=CC=CC=1)C1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-CQSZACIVSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 9
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 208000037012 Psychomotor seizures Diseases 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 | |
| US62/711,051 | 2018-07-27 | ||
| PCT/US2019/043765 WO2020023923A1 (en) | 2018-07-27 | 2019-07-26 | Method for treating epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530541A JP2021530541A (ja) | 2021-11-11 |
| JPWO2020023923A5 true JPWO2020023923A5 (enExample) | 2022-08-02 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503108A Pending JP2021530541A (ja) | 2018-07-27 | 2019-07-26 | てんかんの治療方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200030260A1 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| SG11201804811WA (en) | 2015-12-22 | 2018-07-30 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| KR20180095674A (ko) | 2015-12-22 | 2018-08-27 | 조게닉스 인터내셔널 리미티드 | 대사 저항성 펜플루라민 유사체 및 그 사용 방법 |
| RU2746000C2 (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| WO2020047312A1 (en) * | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| US12144787B2 (en) | 2018-11-19 | 2024-11-19 | Zogenix International Limited | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) |
| CN114127150A (zh) * | 2019-07-18 | 2022-03-01 | 巴斯夫欧洲公司 | 脲基甲酸酯基分散剂 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20230078820A1 (en) * | 2021-09-01 | 2023-03-16 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| WO1995033455A1 (en) * | 1994-06-03 | 1995-12-14 | Elmaleh David R | Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof |
| JP2001524124A (ja) | 1997-05-07 | 2001-11-27 | ガレン（ケミカルズ）リミティド | テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具 |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CA3204599A1 (en) * | 2015-02-25 | 2016-09-01 | The Regents Of The University Of California | 5ht agonists for treating disorders |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 US US16/523,568 patent/US20200030260A1/en active Pending
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277272B1 (en) | Rimegepant for cgrp related disorders | |
| JP2019059760A5 (enExample) | ||
| US20050245460A1 (en) | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders | |
| JP2018520189A5 (enExample) | ||
| US10987324B2 (en) | Methods and compositions for the treatment of seizure-related disorders | |
| US20090253728A1 (en) | Methods and Compositions for Treating Nociceptive Pain | |
| JP2002532392A5 (enExample) | ||
| US20080118556A1 (en) | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone | |
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| EP1874282A2 (en) | Methods and compositions for treatment of cns disorders | |
| JPWO2020023923A5 (enExample) | ||
| JP2010501479A5 (enExample) | ||
| JP2002524415A5 (enExample) | ||
| JP2022153638A5 (enExample) | ||
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| ES2216296T3 (es) | Formulacion farmaceutica que libera de manera controlada, con un agente inhibidor de la ace como sustancia activa. | |
| KR20040028758A (ko) | Ｇｖｇ를 사용하는 강박성 장애(ｏｃｄ) 및 ｏｃｄ-관련장애에 대한 신규의 치료 | |
| RU99119233A (ru) | Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени | |
| CA2684174C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson | |
| WO2014174387A1 (en) | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof | |
| JPWO2021023811A5 (enExample) | ||
| JP2019514935A5 (enExample) | ||
| CA2684171C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| US20090297597A1 (en) | Modified Release Ticlopidine Compositions | |
| EP1901718A1 (en) | Modified release ticlopidine compositions |